VVitenta

News

What changed for people on GLP-1 treatment

Medicines (approvals, safety, access), nutrition and exercise. Only what changes something for you, with the date and the source on every item. No miracle cures, no promises.

Last checked: 16 November 2026
Sources: EMA · FDA · MHRA · medical journals · manufacturers
How we check an item →

November 2026

9 NovMedicinesSafety

Your eyes: a rare sign worth knowing

For you: if the vision in one eye drops suddenly and without pain, see a doctor the same day. It is rare, and knowing the sign gets you checked quickly.

Source: FDA — Drug Safety Communication, 9 November 2026 · EMA — PRAC: NAION a very rare side effect of semaglutide, 6 June 2025MounjaroOzempicWegovy
9 NovExerciseStudy

Strength training keeps muscle and builds strength during treatment

For you: three strength sessions a week. In the study, people who trained got stronger while losing about the same weight.

Source: University of Western Australia — news release on the T-REx study (Green et al., Nature Medicine, 2026)Mounjaro

October 2026

26 OctNutritionStudy

Protein in the first months of treatment: most people eat less than they think

For you: check your target in the protein calculator. It is easy to fix with ordinary food.

Source: Ramel A. — Dietary intake and weight loss in obese adults during GLP-1 receptor agonist treatment, European Journal of Public Health, 2026;36(Suppl 5)
15 OctMedicinesApprovals

The daily GLP-1 pill Foundayo: already in the US and the UK, now recommended for the EU

For you: in the US and the UK it is available on prescription. In the EU it is not in pharmacies yet.

Source: EMA — New oral GLP-1 medicine for weight management and type 2 diabetes, 16 October 2026 · MHRA — UK first in Europe to authorise orforglipron, 10 August 2026 · AJMC — FDA approves Lilly's oral GLP-1 orforglipron for obesity, 1 April 2026

September 2026

29 SepMedicinesStudy

Research moves forward: the main retatrutide trial is published

For you: it is still an investigational medicine. The treatment you have now is the one to follow.

Source: New England Journal of Medicine, 29 September 2026 (Jastreboff et al., TRIUMPH-1) — reported by Scientific American · Eli Lilly — TRIUMPH-2 and TRIUMPH-3 results, 23 July 2026 · Reuters via FOX 9 — Eli Lilly offers retatrutide to some patients before FDA approval, 7 August 2026

Is something missing on Vitenta?

Tell us what to add or what wasn't clear. Anonymous — no name, e-mail or phone.

What you write reaches only the team and is never shown on the site. Any content change is checked against the official leaflet.

Your suggestion
0/500 characters

Please don't include personal details.